The majority of these patients received two vaccine doses at least
five months ago, are over the age of 60 and also have chronic
illnesses known to exacerbate a coronavirus infection. They range
from diabetes to heart disease and lung ailments, as well as cancers
and inflammatory diseases that are treated with immune-system
suppressing drugs, according to Reuters interviews with 11 doctors,
health specialists and officials. Such "breakthrough" cases have
become central to a global debate over whether highly vaccinated
countries should give booster doses of COVID-19 vaccines, and to
which people.
Israel began offering booster doses to people age 60 and up in July,
and has since expanded that eligibility.
The United States, citing data out of Israel and other findings,
said on Wednesday it would make booster doses available to all
Americans beginning in September.
Other countries, including France and Germany, have so far limited
their booster plans to the elderly and people with weak immune
systems. "The vaccinated patients are older, unhealthy, often they
were bedridden before infection, immobile and already requiring
nursing care," said Noa Eliakim-Raz, head of the coronavirus ward at
Rabin Medical Centre in Petach Tikva. In contrast, "the unvaccinated
COVID patients we see are young, healthy, working people and their
condition deteriorates rapidly," she said. "Suddenly they're being
put on oxygen or on a respirator." Israel's Health Ministry raised
new alarm this week with a report showing the effectiveness against
severe disease of the Pfizer vaccine, developed with Germany's
BioNTech, appeared to have dropped from more than 90% to 55% in
people age 65 and up who received their second jab in January.
Disease experts say it is not clear how representative the figures
are, but agree it is concerning given evidence that overall vaccine
protection against infection is waning.
They cannot say whether that is due to the amount of time that has
passed since inoculation, the ability of the highly contagious Delta
variant to evade protection, the age and underlying health of the
people vaccinated, or a combination of all of these factors. Health
officials in the UK and United States, two other nations with high
vaccination rates and a spike in Delta infections, have reported
similar trends. In the UK, about 35% of the people hospitalized with
a Delta case in recent weeks had received two doses of a COVID-19
vaccine.
Nearly three-quarters of U.S. breakthrough infections that
led to hospitalization or death were among people age 65 or older,
according to federal data. U.S. officials said their booster plan is
based on concern that over time, the vaccines will provide less
protection against severe disease, including among younger adults.
"We are watching other countries carefully and (are) concerned that
we too will see what Israel is seeing, which is worsening infections
over time" among vaccinated people, U.S. Centers for Disease Control
and Prevention Director Rochelle Walensky said at a press conference
on Wednesday. The World Health Organization has repeatedly urged
wealthy nations to refrain from providing boosters while much of the
world has yet to access their first COVID vaccine doses.
IMMUNE RESPONSE The Delta variant, first identified in India, has
become the dominant version of the SARS-CoV-2 virus globally,
accelerating a pandemic that has killed more than 4.4 million
people. In Israel, daily new cases have increased from the single
digits in June to around 8,000 since the arrival of Delta.
Approximately half of the cases - the majority of them mild to
moderate - are in vaccinated people. Those vaccinated first in
Israel were at high-risk, including people age 60 and up.
[to top of second column] |
The immune response of some may have weakened by the time Delta hit
Israel. But for others with underlying health conditions, the
vaccine may have not kicked in at all. "For some of them the vaccine
did not trigger an immune response, they had no antibodies, because
of the illness itself or because they are treated with medication
that suppresses the immune system," said Dror Mevorach, who heads
the coronavirus ward at Hadassah hospital in Jerusalem. He cited
examples such as chronic lymphocytic leukemia and lymphoma. Among 3
million vaccinated Israelis covered by Clalit, the country's largest
healthcare provider, 600 have suffered severe breakthrough cases
since June.
Around 75% of them were above the age of 70 and were at least 5
months after their second dose, according to Ran Balicer, Clalit's
chief innovation officer. Nearly all of them have chronic illnesses.
"We are hardly seeing young vaccinated people in severe condition,"
said Balicer.In the UK, doctors described similar characteristics
among vaccinated patients who fall severely ill. "In those people
who come in, because of their age, because of their co-morbidities,
they might be people that you would expect that the vaccine is not
quite so efficacious as other age groups," said Tom Wingfield, a
clinical lecturer at the Liverpool School of Tropical Medicine.
A new surge in U.S. coronavirus cases and deaths has been fueled by
Delta, particularly in states where vaccination rates remain low.
Among vaccinated patients who become infected, there is evidence of
older people being hit harder. In Texas, 92% of the vaccine
breakthrough cases that resulted in death were in people over the
age of 60 and 75% had a known underlying condition that put them at
high risk from COVID-19, according to a public health department
spokesperson. Initial data in Israel suggests the booster shots
administered in the last few weeks are reducing the risk of
infection in older people compared with those who have received only
two doses..
Even without boosters, Israeli doctors say that vaccinated patients
tend to recover more quickly. "The vaccinated patients I've treated
usually left the ICU in about three days. The unvaccinated patients
took a week or two until they stabilized," said Yael Haviv-Yadid,
head of the critical care ward at Sheba Medical Centre near Tel
Aviv. Even if the vaccine did not stop them getting ill, it may have
mitigated their illness, said Alex Rozov, head of the coronavirus
ward at Barzilai Medical Centre in Ashkelon.
"Our cautious impression is that the vaccinated patients suffer an
easier course of illness - the treatment is more effective among
those who have antibodies."
(Additional reporting by Alistair Smout and Josephine Mason in
London, Carl O'Donnell in New York; Editing by Michele Gershberg and
Dan Grebler)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content
|